The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions ...

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I ...

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...

In a Day 1 executive order, President Donald Trump withdrew from the landmark climate accord. Additional orders on energy are expected.

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...

Privately owned Blue Origin has achieved its goal—a decade in the making—of becoming an orbital launch player, even as it ...

The ChristianaCare Health Network has officially become the second group of doctors and the first house staff in Delaware to ...

New to Kayo? Get your first month for just $1. Limited time offer. Appo, 25, has spent the past two seasons playing with the Bradford Bulls in the second-tier RFL Championship in the UK.

While there’s no universal consensus for the best Genshin Impact character of 5.3 Phase 1, the choice either comes down to wanting a DPS character with good off-field damage or a support character ...

College of Materials, Institute of Artificial Intelligence, State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, iChEM, Fujian Key Laboratory of ...